InfuSystem Holdings Inc
AMEX:INFU
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
4.7
10.78
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
InfuSystem Holdings Inc
InfuSystem Holdings, Inc. engages in the provision of healthcare services. The company is headquartered in Rochester Hills, Michigan and currently employs 420 full-time employees. The company went IPO on 2006-06-15. The Company’s segments include Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). The Company’s core service within its ITS segment is its Oncology Business. The ITS segment supplies electronic ambulatory infusion pumps and associated disposable supply kits to private oncology clinics, infusion clinics and hospital outpatient oncology clinics to be utilized in the treatment of a variety of cancers, including colorectal cancer and other disease states. Its DME Services segments core service is to sell or rent new and pre-owned pole-mounted and ambulatory infusion pumps and other Durable Medical Equipment; sell treatment-related consumables; and provide biomedical recertification, maintenance and repair services for oncology practices as well as other healthcare site settings.
InfuSystem Holdings, Inc. engages in the provision of healthcare services. The company is headquartered in Rochester Hills, Michigan and currently employs 420 full-time employees. The company went IPO on 2006-06-15. The Company’s segments include Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). The Company’s core service within its ITS segment is its Oncology Business. The ITS segment supplies electronic ambulatory infusion pumps and associated disposable supply kits to private oncology clinics, infusion clinics and hospital outpatient oncology clinics to be utilized in the treatment of a variety of cancers, including colorectal cancer and other disease states. Its DME Services segments core service is to sell or rent new and pre-owned pole-mounted and ambulatory infusion pumps and other Durable Medical Equipment; sell treatment-related consumables; and provide biomedical recertification, maintenance and repair services for oncology practices as well as other healthcare site settings.
Record Revenue: InfuSystem reported record third quarter 2025 revenue of $36.5 million, up 3.3% from the prior year.
Margin Expansion: Gross margin reached just over 57%, up 3.1 percentage points year-over-year, with gross profit also a quarterly record.
Profitable Growth: Adjusted EBITDA rose 5.6% to $8.3 million, representing 22.8% of net revenue, even with significant ERP investment.
Wound Care & Oncology Strength: Wound Care revenue more than doubled, and Oncology revenue hit an all-time record, benefiting from new contracts and increased patient volumes.
Biomedical Contract Change: Major biomedical services contract restructured, reducing revenue by $6–7 million annually starting December, but expected to increase operating profit due to lower costs.
Cash Flow & Capital Return: Year-to-date operating cash flow exceeded $17 million, with $8.6 million returned to shareholders via buybacks and net debt reduced by $5.7 million in Q3.
Guidance Reaffirmed: Full-year 2025 outlook reaffirmed: revenue growth of 6–8% and adjusted EBITDA margin of at least 20%.